Scalper1 News
British drug giant AstraZeneca (AZN) agreed to buy full ownership of the diabetes program it’s been sharing with Bristol-Myers Squibb (BMY), thus ending Bristol’s attempt at being a diabetes powerhouse. Both stocks were up on the stock market today. AstraZeneca agreed to pay $2.7 billion upfront for the assets, which include several marketed drugs such as Bydureon, Byetta and Onglyza, as well as $1.4 billion in regulatory and milestone payments Scalper1 News
Scalper1 News